We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Bart Burgess, Director, Business Development, Self-Injection Systems at West, and Peter Krulevitch, Ph.D., Engineering Director, Packaging, Devices & Delivery at Janssen Pharmaceutical Companies of Johnson & Johnson will present “A New Self-Injection Technology and Unique Partnership” at the Drug Delivery Partnership Conference. The conference will be held February 6-8, 2013, at the Hilton San Diego Bayfront, San Diego, CA.
Bart and Peter will discuss self-injection technology and the partnership between West and Janssen to develop the SelfDoseTM* injector platform technology.
West’s SelfDose system provides an integrated drug delivery solution designed to ease self-injection. Further, the integrated passive needle helps mitigate the risk of accidental needlestick injuries. The SelfDose system offers a convenient and easy-to-use solution for a wide range of drug products.
For more information or to register to attend the conference, visit: http://www.iirusa.com/ddp/agenda-at-a-%20Glance.xml.
*For investigational use only for our pharmaceutical and biotechnology development partners.
SelfDose™ is a trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. West seeks partners for its SelfDose™ injector technology platform. This platform is intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.
At the 2013 Drug Delivery Partnership conference, West’s Bart Burgess partnered with Peter Krulevitch, Ph.D., Engineering Director, Packaging, Devices & Delivery, Janssen Pharmaceutical Companies of Johnson & Johnson to discuss West and Janssen’s unique partnership. Together, West and Janssen are developing the SelfDose<sup>TM</sup> injector platform technology.*
The drive for high-quality packaging has helped manufacturers focus on increasing consistency of performance in devices such as auto-injector and patch injection systems. In addition, there is an increased focus on providing drug delivery systems that are easy to use. A consistent quality of components can help to improve performance and ensure delivery in the home environment, while user-centric systems can help assist with compliance.
As the adoption and acceptance of self-administered therapies grows, patients are spending less time with physicians and are playing a greater role in the delivery and management of their treatments. With the growing demand for extended-release and high-concentration formulations, more drug delivery systems choices are now available to differentiate drug products in a crowded market. Patient preferences can drive the selection of self-injection systems for a drug therapy. Selecting a system that patients prefer can, simplify use and increase compliance with the dosage regimen.
<span style="color: #000000;">West has completed a preliminary study of its SmartDose® technology platform, which incorporates a Daikyo Crystal Zenith® (CZ) cartridge. The study evaluated multiple attributes of the technology and subjects’ experience with the self-application process. </span>
Polymeric container systems are not new to the pharmaceutical industry, and their benefits in terms of break resistance, cosmetic quality and dimensional precision have been recognized by many companies around the world who have chosen to use a polymer vial or syringe.
English
Chinese
